Inhibrx Biosciences, Inc.
ozekibart (INBRX-109)
locally advanced or metastatic, unresectable colorectal cancer (CRC)
Resolved
97days ago
Phase 1 readout · Apr 1, 2026
What's at stake
Phase 1 trial results for ozekibart (INBRX-109) in locally advanced or metastatic, unresectable colorectal cancer (CRC) are due Apr 1, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“In April 2026, we announced updated interim data from our Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer (CRC);”